<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Almotriptan</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00918</strong>&#160; (APRD00169)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Almotriptan does not prevent migraine attacks.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00918/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00918/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00918.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00918.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00918.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00918.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00918.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00918">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Almogran</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Axert</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/serotonin-antagonists">Serotonin Antagonists</a></li>
<li><a href="/mesh/serotonin-receptor-agonists">Serotonin Receptor Agonists</a></li>
<li><a href="/mesh/anti-migraine-agents">Anti-migraine Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>181183-52-8</td></tr><tr><th>Weight</th><td>Average: 335.464<br>Monoisotopic: 335.166747749</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>WKEMJKQOLOHJLZ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">dimethyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Indoles and Derivatives</td></tr><tr><th>Subclass</th><td>Tryptamines and Derivatives</td></tr><tr><th>Direct parent</th><td>Tryptamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Indoles; Benzene and Substituted Derivatives; Substituted Pyrroles; Sulfonamides; Pyrrolidines; Sulfonyls; Tertiary Amines; Polyamines</td></tr><tr><th>Substituents</th><td>indole; substituted pyrrole; benzene; sulfonyl; sulfonamide; pyrrole; sulfonic acid derivative; pyrrolidine; tertiary amine; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring subsituted at the thrid position by an ethanamine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of acute migraine headache in adults</td></tr><tr><th>Pharmacodynamics</th><td>Almotriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Almotriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT<sub>1D</sub> family) having only a weak affinity for 5-HT<sub>1A</sub>, 5-HT<sub>5A</sub>, and 5-HT<sub>7</sub> receptors and no significant affinity or pharmacological activity at 5-HT<sub>2</sub>, 5-HT<sub>3</sub> or 5-HT<sub>4</sub> receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Almotriptan also activates 5-HT<sub>1</sub> receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Almotriptan in humans.</td></tr><tr><th>Mechanism of action</th><td>Almotriptan binds with high affinity to human 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors leading to cranial blood vessel constriction.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>180 to 200 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>35%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Almotriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003533" target="_blank">Cytochrome P450 2E1</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET00347">N-desmethylalmotriptan</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/349">Details</a></td></tr><tr><td>Almotriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002198" target="_blank">Amine oxidase [flavin-containing] A</a></li></ul></td><td><a href="/metabolites/DBMET00469">2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}acetic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/478">Details</a></td></tr><tr><td>Almotriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002198" target="_blank">Amine oxidase [flavin-containing] A</a></li></ul></td><td><a href="/metabolites/DBMET00472">2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethan-1-ol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/481">Details</a></td></tr><tr><td>Almotriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00473">1-[({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methane)sulfonyl]pyrrolidin-2-ol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/482">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Almotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized.</td></tr><tr><th>Half life</th><td>3-4 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>57 L/h [healthy]</li>
	<li>34.2 L/h [moderate renal impairment (creatinine clearance between 31 and 71 mL/min)]</li>
	<li>9.8 L/h [severe renal impairment (creatinine clearance between 10 and 30 mL/min)]</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3<br>Gene symbol: GNB3<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P16520" target="_blank">P16520 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs5443" target="_blank">rs5443 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T Allele</td><td>Better response to drug treatment</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17361120" target="_blank" title="Schurks M, Kurth T, Stude P, Rimmbach C, de Jesus J, Jonjic M, Diener HC, Rosskopf D: G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther. 2007 Oct;82(4):396-401. Epub 2007 Mar 14.">17361120 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9781</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7421</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5636</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8282</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8679</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.553</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6292</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.605</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8089</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6273</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8581</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8929</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8486</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6532
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8588
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9508
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5976 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.5255
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6008
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Ortho mcneil janssen pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li>McNeil Laboratories</li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho-McNeil-Janssen Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan. Use an initial almotriptan dose of 6.25mg when using almotriptan with a strong CYP3A4 inhibitor, and do not exceed 12.5mg of almotriptan in any 24-hour period. Avoid concurrent use of almotriptan with a strong CYP3A4 inhibitor in patients with impaired hepatic or renal function.</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01253">Ergonovine</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan</td></tr><tr><td><a href="/drugs/DB00353">Methylergometrine</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Almotriptan. Risk of serotonin syndrome and Almotriptan toxicity. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of almotriptan by decreasing its metabolism. The initial and maximum doses should not exceed 6.25 mg and 12.5 mg, respectively during concomitant therapy. Concomitant therapy should be avoided in patients with impaired hepatic or renal function. </td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and almotriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li>
<li>The absorption is unaffected by food.</li></ul></td></tr></tbody></table>